Microwave ablation versus surgical resection for hepatocellular carcinoma within Milan criteria: A propensity score-based analysis.
TL;DR
Microwave ablation demonstrated comparable RBM, OS, and RFS outcomes to SR in HCC patients within Milan criteria, indicating that MWA represents an effective local treatment alternative in this patient population.
OpenAlex 토픽 ·
Hepatocellular Carcinoma Treatment and Prognosis
Cholangiocarcinoma and Gallbladder Cancer Studies
Genetic and Kidney Cyst Diseases
Microwave ablation demonstrated comparable RBM, OS, and RFS outcomes to SR in HCC patients within Milan criteria, indicating that MWA represents an effective local treatment alternative in this patien
- 표본수 (n) 187
- p-value P = 0.032
- p-value P < 0.001
- 95% CI 0.71-1.63
- HR 1.08
APA
Qi Xu, Peng Zhang, et al. (2026). Microwave ablation versus surgical resection for hepatocellular carcinoma within Milan criteria: A propensity score-based analysis.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 52(5), 111510. https://doi.org/10.1016/j.ejso.2026.111510
MLA
Qi Xu, et al.. "Microwave ablation versus surgical resection for hepatocellular carcinoma within Milan criteria: A propensity score-based analysis.." European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 52, no. 5, 2026, pp. 111510.
PMID
41819052
Abstract
[OBJECTIVES] Microwave ablation (MWA) has emerged as an important local treatment option for patients with hepatocellular carcinoma (HCC) within the Milan criteria. This study aimed to compare the recurrence beyond the Milan criteria (RBM) rates between MWA and surgical resection (SR) in HCC patients.
[METHODS] This retrospective multicenter study included 668 patients with Milan criteria HCC who underwent initial treatment with either MWA or SR between January 2010 and December 2023. Baseline characteristics were balanced using propensity score matching (PSM) and inverse probability of treatment weighting (IPTW). RBM, overall survival (OS), and recurrence-free survival (RFS) were compared between the two groups using the log-rank test.
[RESULTS] A total of 668 patients (mean age, 60.1 ± 9.6 years; 532 male) were included. After PSM (n = 187 in each group), the 1-, 3-, and 5-year RBM rates were 26.5%, 40.9%, and 56.5% in the MWA group, and 18.1%, 42.7%, and 61.7% in the SR group, respectively (hazard ratio [HR] = 0.95, 95% confidence interval [CI] 0.70-1.29; P = 0.751). The corresponding OS rates were 92.9%, 81.0%, and 66.9% in the MWA group, and 95.1%, 85.6%, and 70.1% in the SR group (HR = 1.08, 95% CI 0.71-1.63; P = 0.727). The 1-, 3-, and 5-year RFS rates were 69.2%, 42.3%, and 27.8% in the MWA group, compared with 75.0%, 46.3%, and 27.3% in the SR group (HR = 1.08, 95% CI 0.83-1.39; P = 0.579). After IPTW adjustment, no significant differences were observed between the two groups in RBM (HR = 1.01, 95% CI 0.75-1.35; P = 0.969), OS (HR = 0.84, 95% CI 0.57-1.23; P = 0.372), or RFS (HR = 1.04, 95% CI 0.82-1.32; P = 0.733). In the PSM cohort, the MWA group had significantly fewer postoperative complications than the SR group (24.6% vs. 35.3%; P = 0.032) and a shorter length of hospital stay (median, 4 [IQR, 3-5.5] vs. 8 [IQR, 5-10] days; P < 0.001).
[CONCLUSION] MWA demonstrated comparable RBM, OS, and RFS outcomes to SR in HCC patients within Milan criteria. Given its lower morbidity and shorter hospitalization, MWA represents an effective local treatment alternative in this patient population.
[METHODS] This retrospective multicenter study included 668 patients with Milan criteria HCC who underwent initial treatment with either MWA or SR between January 2010 and December 2023. Baseline characteristics were balanced using propensity score matching (PSM) and inverse probability of treatment weighting (IPTW). RBM, overall survival (OS), and recurrence-free survival (RFS) were compared between the two groups using the log-rank test.
[RESULTS] A total of 668 patients (mean age, 60.1 ± 9.6 years; 532 male) were included. After PSM (n = 187 in each group), the 1-, 3-, and 5-year RBM rates were 26.5%, 40.9%, and 56.5% in the MWA group, and 18.1%, 42.7%, and 61.7% in the SR group, respectively (hazard ratio [HR] = 0.95, 95% confidence interval [CI] 0.70-1.29; P = 0.751). The corresponding OS rates were 92.9%, 81.0%, and 66.9% in the MWA group, and 95.1%, 85.6%, and 70.1% in the SR group (HR = 1.08, 95% CI 0.71-1.63; P = 0.727). The 1-, 3-, and 5-year RFS rates were 69.2%, 42.3%, and 27.8% in the MWA group, compared with 75.0%, 46.3%, and 27.3% in the SR group (HR = 1.08, 95% CI 0.83-1.39; P = 0.579). After IPTW adjustment, no significant differences were observed between the two groups in RBM (HR = 1.01, 95% CI 0.75-1.35; P = 0.969), OS (HR = 0.84, 95% CI 0.57-1.23; P = 0.372), or RFS (HR = 1.04, 95% CI 0.82-1.32; P = 0.733). In the PSM cohort, the MWA group had significantly fewer postoperative complications than the SR group (24.6% vs. 35.3%; P = 0.032) and a shorter length of hospital stay (median, 4 [IQR, 3-5.5] vs. 8 [IQR, 5-10] days; P < 0.001).
[CONCLUSION] MWA demonstrated comparable RBM, OS, and RFS outcomes to SR in HCC patients within Milan criteria. Given its lower morbidity and shorter hospitalization, MWA represents an effective local treatment alternative in this patient population.
MeSH Terms
Humans; Carcinoma, Hepatocellular; Liver Neoplasms; Male; Female; Propensity Score; Middle Aged; Retrospective Studies; Microwaves; Hepatectomy; Aged; Survival Rate; Neoplasm Recurrence, Local; Radiofrequency Ablation
같은 제1저자의 인용 많은 논문 (5)
- Integrated pharmacokinetic properties, tissue distribution and metabolism of multiple active constituents in DBD for the treatment of GEM-induced myelosuppression.
- Synergistic DBNDD1-GDF15 Signaling Activates the NF-κB Pathway to Promote Colorectal Cancer Progression.
- Efficacy, safety, and biomarkers of neoadjuvant trastuzumab and pertuzumab combined with chemotherapy in Chinese patients with HER2-positive breast cancer: a multicenter retrospective cohort study.
- Modulating to boost anti-PD-1 immunotherapy in HCC.
- Integrative single-cell and spatial transcriptomic analysis reveals lipid metabolism-mediated macrophage heterogeneity during colorectal cancer liver metastasis progression.